Traws Pharma CFO files initial Form 3

Traws Pharma, Inc. filed an initial ownership report for Chief Financial Officer Parker Charles Nolan on Form 3.

Accepted by SEC EDGAR 04/08/2026 - 02:46 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Traws Pharma, Inc. filed an initial ownership report for Chief Financial Officer Parker Charles Nolan on Form 3. The filing lists Nolan as an officer but shows no reportable transactions or holdings in the summarized data, serving as a baseline disclosure of his insider status.

Key Terms

Form 3, Chief Financial Officer, reporting person

3 terms

Form 3 regulatory

"filed an initial ownership report for Chief Financial Officer on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Financial Officer financial

"identifies Parker Charles Nolan as Chief Financial Officer"

A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.

reporting person regulatory

"The reporting person is Parker Charles Nolan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the TRAW Form 3 filing for Parker Charles Nolan show?

The Form 3 filing for Traws Pharma, Inc. identifies Parker Charles Nolan as Chief Financial Officer. It functions as an initial insider ownership report and, in the provided data, shows no reportable transactions or derivative positions.

Who is the reporting person in the Traws Pharma (TRAW) Form 3?

The reporting person is Parker Charles Nolan, listed as Chief Financial Officer of Traws Pharma, Inc. This establishes him as a company insider subject to ongoing ownership reporting rules under Form 4 and Form 5 when future transactions occur.

Are there any buy or sell transactions reported in this TRAW Form 3?

No buy or sell transactions appear in the summarized Form 3 data for Traws Pharma, Inc. All transaction counters, including buy, sell, exercise, gifts, and tax withholding, are shown as zero in the transaction summary section.

Does the Traws Pharma (TRAW) Form 3 show any derivative securities?

The provided Form 3 data for Traws Pharma, Inc. lists no derivative securities. The derivative summary is empty and derivativeTransactionCount is zero, indicating no reportable options, warrants, or similar instruments in this snapshot.

Why is Form 3 important for Traws Pharma (TRAW) investors?

Form 3 is important because it establishes the baseline ownership status of new insiders at Traws Pharma, Inc. Future Forms 4 and 5 will reference this baseline when disclosing changes in insider holdings and transactions over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Parker Charles Nolan

(Last) (First) (Middle)

C/O TRAWS PHARMA, INC

12 PENNS TRAIL

(Street)

NEWTOWN PENNSYLVANIA 18940

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/03/2025

3. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Charles N. Parker	04/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)